Marqibo and Neoral

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

CycloSPORINE can increase the blood levels and effects of some chemotherapy medications such as vinCRIStine liposome. You may be more likely to experience side effects such as nausea, vomiting, and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Limited data suggest that cyclosporine given to reverse multidrug resistance can enhance the toxicity of some antineoplastic agents such as dactinomycin and vincristine. The proposed mechanism is cyclosporine inhibition of multidrug resistance protein 1 (MDR1), also known as P-glycoprotein, a plasma membrane efflux transporter that has been demonstrated as a primary cause of multidrug resistance in tumors. Inhibiting P-glycoprotein increases the intracellular concentration of substrate antineoplastic agents, thereby potentiating their cytotoxic effects.

MANAGEMENT: Patients receiving antineoplastic agents that are known substrates of P-glycoprotein should be closely monitored for potentially increased toxicities during coadministration with cyclosporine, and their dosages adjusted as necessary.

Marqibo

Generic Name: vincristine liposome

Brand name: Marqibo

Synonyms: n.a.

What is Marqibo?

Neoral

Generic Name: cyclosporine

Brand name: Gengraf, Neoral, Sandimmune, Sandimmune

Synonyms: Neoral (Capsules, Modified)

What is Neoral?